Rose Gerber, director of patient advocacy and education for the Community Oncology Alliance, discusses the importance of patient education in encouraging clinical trial participation, as well as the importance of trials being patient centered.
Rose Gerber, director of patient advocacy and education for the Community Oncology Alliance, discusses the importance of patient education in encouraging clinical trial participation, as well as the importance of trials being patient centered.
Transcript
How important of a role does education play in encouraging clinical trial participation?
I think the education component is really important because when a patient is sitting in front of their doctor and they’re just having that simple dialogue, it’s building trust. Pretty much the entire population sees an oncologist or any doctor as a very competent individual. So, when they’re sitting there and their doctor is telling them about all the risks and benefits of a trial, I think that starts to put the patient’s mind at ease.
While clinical trials are important for collecting data on a drug, why is it important to make sure that trials are patient centered?
I think patient centricity is something that’s a buzz word right now, but really what it means is we really want to make sure that even though scientists have their goals and the goal of testing a new drug is to determine the outcomes, we need to remember there is a real live person this drug is being tested on and the person is not a robot; this is someone with a heart, feelings, emotions, and fears. Especially when you’re newly diagnosed, that’s when you’re the most vulnerable. So, anytime there’s a group of people planning a research study, whether these are the researchers or the oncologist, you need to really think of the patient because that’s actually who it’s going to impact—a real life human being.
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Neurologists Share Tips for Securing Patient Access to Gene Therapies
March 19th 2025Tenacious efforts at every level, from the individual clinician to the hospital to the state to Congress, will be needed to make sure patients can access life-saving gene therapies for neuromuscular diseases.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
EMBARK Data Show Continued Improvements With DMD Gene Therapy
March 19th 2025Data from the EMBARK trial of delandistrogene moxeparvovec in patients with Duchenne muscular dystrophy (DMD) show that benefits in functional outcomes, gene expression, and muscle imaging persist 2 years after receiving the gene therapy.
Read More
How Access to SMA Treatment Varies Globally and by Insurance Type
March 18th 2025Posters presented at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference show that therapeutic advances in treating spinal muscular atrophy (SMA) are not uniformly making it into the hands of patients who could benefit.
Read More